| Prev Close | 248.04 |
| Open | 249.44 |
| Day Low/High | 247.89 / 255.30 |
| 52 Wk Low/High | 143.13 / 275.87 |
| Volume | 3.24M |
Eli Lilly and Company (LLY)
249.24
1.20
0.48
NYSE
| Exchange | NYSE |
| Shares Outstanding | 956.59B |
| Market Cap | 243.77B |
| P/E Ratio | 33.79 |
| Div & Yield | N.A. (N.A) |
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
A Handful of Small Biotechs That Make for Merger Chatter
The names include a veterinary drug concern plus companies with successful drugs on the market.
IPO Gives Chinese Couple a 'Hansoh' Sum
The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.
Eli Lilly Broke Below the 200-Day Average to Change the Narrative to Bearish
Let's step back and look at the bigger picture through charts and indicators.
Jim Cramer: A Tale of Two Stocks
I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.
Thor Industries and Eli Lilly Offer a Tale of Two Stocks
The charts of the maker of recreational vehicles are bearish, while the drugmaker appears to be a buy
China's Drugmakers Under Scrutiny After Stanford Admissions Scandal
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
Teva Pharmaceuticals CEO: Stock on Track for 2020 Turnaround
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
Jim Cramer: Diversification Is Good for Offense, Not Just Defense
This health care selloff shows the value of diversification to protect our portfolios -- and to go on the offensive and find bargains.
Jim Cramer: Want a Snapshot of the Economy? Look at the Rails
When you see that money pouring out of the market it is going to be looking for a home. The home will most likely want some economic sensitivity.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Activists Aim to Eliminate Dual Role for Allergan CEO Saunders
David Tepper's Appaloosa LP renews calls for changes at the top.
Jim Cramer: How to Win Now, With or Without China
If we can advance without China then who the heck knows where we can go with it.
3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis
Pets can bring significant profits to companies that cater to this niche market.
Small-Caps Are Making Big Moves in This Technically Extended Market
Focus on individual stock picking, and take a look at small-caps, as earnings season continues.
Take Some Profits on This Strength: Market Recon
The market can still go higher, but the time has come for the slope of price discovery to normalize a bit.
Eli Lilly Is Trading Strong Ahead of Earnings on Wednesday
Jim Cramer said that Eli Lilly was the best of the pharmaceutical companies as he looked at the companies reporting earnings this week.
Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil
These themes are working despite the turmoil in Washington and slowing global growth.
Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative
So far 2019 is proving to be a year where things have a habit of working out right.
Jim Cramer: There's a Ton More Deals in the Pipe
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
Goldman's Gold Standard in M&A Bolsters Outlook for 2019
Goldman is top of the heap for takeovers.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon
Do we have to run for the hills? Not necessarily.
This Market May Just Be in an Uptrend: Market Recon
This is the kind of reversal that happens in a bull market.
Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Jim Cramer: These Pharma Deals Are Game Changers
Pharma companies that have cash are looking at what has happened to this stock market and buying.
Jim Cramer: They Might Be Done
Whether this is the end of the slump is still up for debate, but the crash since October has been brutal and all bear markets end the same way.
Eli Lilly's Technical Setup Looks So-So, So Be Ready to Take Action
A close below $105 for the drugmaker's shares would be bearish based on its charts.
3 Tips for Trading the Fed's More Dovish Stance
Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?
